A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Neoadjuvant therapy is feasible in stage II melanoma, and the dual inhibition of the distinct LAG-3 and PD-1 checkpoint pathways with relatlimab and nivolumab has a synergistic effect in the tumour microenvironment leading to a pathological response after 2 doses of therapy.
Epistemonikos ID: 6731ba119731591198eecd75341cdf083c244aa0
First added on: May 13, 2024